Incidence of Discontinuation of Highly Active Antiretroviral Combination Therapy (HAART) and Its Determinants
- 1 March 1999
- journal article
- research article
- Published by Wolters Kluwer Health in JAIDS Journal of Acquired Immune Deficiency Syndromes
- Vol. 20 (3) , 290-294
- https://doi.org/10.1097/00042560-199903010-00012
Abstract
To determine the incidence and determinants for discontinuation of initial highly active antiretroviral therapy (HAART). In this retrospective follow-up study from hospital files and pharmacy dispensing data, a standard dataset was collected including patient characteristics, therapy characteristics, and HIV-monitoring parameters (e.g., CD4+ lymphocyte counts, viral load determinations). Kaplan-Meier estimates of the cumulative probability of discontinuation of initial HAART were calculated. Cox proportional hazard analysis was used to identify determinants for discontinuation of initial HAART. All patients starting HAART (n = 99) during June 1996 to February 1997 at our regional AIDS center. Incidence and determinants for discontinuation of HAART. During the mean follow-up of 450 ± 10 days, 27 patients switched initial HAART, 3 patients stopped any antiretroviral therapy. Reasons for switching were increasing viral load (18x), insufficient decrease of viral load (3×), and adverse events (6×). Nonnaivete for antiretroviral therapy and a lower CD4+ lymphocyte count at start were identified as determinants for discontinuation of initial HAART. The overall incidence density for discontinuation of initial HAART was 25 per 100 patients/year. The main reason for switching was an increasing viral load. CD4+ lymphocyte counts at start and nonnaivete for antiretroviral therapy were identified as determinants for discontinuation.Keywords
This publication has 14 references indexed in Scilit:
- Safety and efficacy of two different triple drug combinations in which either lamivudine or didanosine were administered with stavudine plus indinavirAIDS, 1997
- Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: prospective multicentre studyBMJ, 1997
- Treatment with Indinavir, Zidovudine, and Lamivudine in Adults with Human Immunodeficiency Virus Infection and Prior Antiretroviral TherapyNew England Journal of Medicine, 1997
- A Controlled Trial of Two Nucleoside Analogues plus Indinavir in Persons with Human Immunodeficiency Virus Infection and CD4 Cell Counts of 200 per Cubic Millimeter or LessNew England Journal of Medicine, 1997
- Antiretroviral therapy for HIV infection in 1997. Updated recommendations of the International AIDS Society-USA panelPublished by American Medical Association (AMA) ,1997
- British HIV Association guidelines for antiretroviral treatment of HIV seropositive individualsThe Lancet, 1997
- Ordered accumulation of mutations in HIV protease confers resistance to ritonavirNature Medicine, 1996
- Treatment of Human Immunodeficiency Virus Infection with Saquinavir, Zidovudine, and ZalcitabineNew England Journal of Medicine, 1996
- Detection of human immunodeficiency virus type 1 clinical isolates with reduced sensitivity to zidovudine and dideoxyinosine by RNA.RNA hybridization.Proceedings of the National Academy of Sciences, 1991
- Active human immunodeficiency virus protease is required for viral infectivity.Proceedings of the National Academy of Sciences, 1988